AstraZeneca's AZD0780 has demonstrated significant efficacy in a Phase IIb trial, showing a 50.7% reduction in LDL-C after 12 weeks when added to standard statin therapy. The treatment helped 84% of ...

New data from the PURSUIT Phase IIb trial reveal AstraZeneca‘s investigational oral PCSK9 inhibitor, AZD0780, delivers ...

AstraZeneca’s AZD0780 is an investigational oral medication that was developed to lower low-density lipoprotein cholesterol (LDL-C).

AstraZeneca has revealed phase 2b results with its oral PCSK9 inhibitor AZD0780, including a more than 50% reduction in LDL-cholesterol when added to standard therapy, as it tries to narrow a lead ...

An investigational PCSK9 inhibitor with a different mechanism from existing drugs in this class has been shown to safely and ...

Results from the PURSUIT Phase IIb trial for AstraZeneca’s (AZN) AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol reduction when administered on top of ...

Positive results from the PURSUIT phase IIb trial for AstraZeneca’s AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol (LDL-C) reduction when administered on top of ...

In a phase 2b study, treatment with a once-daily oral PCSK9 inhibitor added to statin therapy resulted in a more than 50% ...

AstraZeneca used the American College of Cardiology conference today to unveil data from a phase 2 study of 428 patients with the condition who received one of four doses of AZD0780 or placebo ...